International Edition
Latest News
Business

Novo Nordisk Buybacks Covered by Free Cash Flow, Not Balance Sheet

Novo Nordisk's share buybacks are being funded entirely by operating cash flow rather than balance‑sheet borrowing, according to the company's nine‑month cash‑flow statement released alongside its latest weekly purchase disclosure. In the week of November 9 the Danish…

Novo Nordisk Buybacks Covered by Free Cash Flow, Not Balance Sheet

Novo Nordisk's share buybacks are being funded entirely by operating cash flow rather than balance‑sheet borrowing, according to the company's nine‑month cash‑flow statement released alongside its latest weekly purchase disclosure.

In the week of November 9 the Danish drugmaker bought 1.13 million B shares for 310 million Danish kroner, bringing the twelve‑month total to 12.1 billion kroner — about 81 percent of the 15 billion kroner ceiling authorized for the programme.

Since February 4 the company has repurchased shares almost weekly. A tranche capped at 11.2 billion kroner that began on May 6 had consumed 8.3 billion kroner by November 13. After the latest purchases Novo Nordisk holds treasury stock equal to 1.3 percent of its total share capital.

The cash‑flow statement for January through September shows free cash inflow of 83.8 billion kroner. During the same period 10 billion kroner went to buybacks and 51.9 billion kroner to dividends, leaving a surplus of 21.9 billion kroner. Buybacks therefore absorbed only about 12 percent of free cash flow, and the post‑dividend surplus was more than twice the amount spent on repurchases.

Novo Nordisk cautions that the nine‑month figure is inflated by timing shifts in operating expenses, U.S. rebates and tax payments that will reverse in the fourth quarter. The company said the full‑year accounts, due on February 3 2027, will show how much of that buffer remains. The current tranche is scheduled to end on February 1 2027, though no final announcement for that date has been made.

Novo Nordisk traces its roots to two rival Danish insulin pioneers founded in the 1920s — Nordisk Insulin Laboratorium and Novo Terapeutisk Laboratorium — that competed for decades before merging in 1989 to create the modern company. At the time of the merger the combined group employed 7,350 people; today it has roughly 69,500 staff in 80 countries and sells its medicines in about 170 markets.

At September 30 net debt stood at 79.7 billion kroner against equity of 217.8 billion kroner, a gearing of roughly 37 percent, according to Boerse Express. Because operating cash flow has so far covered both dividends and buybacks with a wide margin, the repurchases have not competed with other corporate spending.

About the author: Business Desk

Business Desk at Archynewsy.